Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00794963 · ClinicalTrials.gov registry record · NA
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
A NA study, sponsored by Northwell Health.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT00794963 is a NA study that was terminated before completion, run by Northwell Health. The registered enrollment target is 8 participants.
The verdict
NCT00794963, a NA study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes. The study will investigate whether structured treatment provided at the site of the outpatient psychiatric clinic of metabolic syndrome in this population will decrease the severity of metabolic syndrome as compared with usual care received by these patients in the community.
Interventions
- DRUG Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan
- OTHER As selected by community physician
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00794963
The ClinicalTrials.gov registry entry for NCT00794963 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan is the first listed.
NCT00794963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00794963 about?
NCT00794963 is a clinical study titled "Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia". Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes. The study will investigate whether structured treatment provided at the site ...
What is the current status of trial NCT00794963?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2008-11. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00794963?
The interventions under investigation include: Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan (DRUG), As selected by community physician (OTHER).
Who is sponsoring clinical trial NCT00794963?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.